Blood Advances

Article	Citations
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer	484
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19	315
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease	291
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma	289
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma	266
A neutrophil activation signature predicts critical illness and mortality in COVID-19	236
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma	226
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease	186
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients	142
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1	135
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma	134
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub	125
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia	122
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia	117
How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT	115
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML	115
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease	114
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma	114
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations	107
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia	105
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19	105
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML	102
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data	102
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience	100
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge	92

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma	87
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy	83
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A	81
Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial	81
Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy	78
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells	77
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients	77
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease	76
Next-generation cell therapies: the emerging role of CAR-NK cells	73
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis	72
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma	71
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide	69
The incidence of cancer-associated thrombosis is increasing over time	69
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia	69
BiTEs better than CAR T cells	68
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations	68
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma	67
Inflammasome activation in neutrophils of patients with severe COVID-19	66
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity	66
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis	64
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy	64
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia	63
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy	63
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort	63
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial	62
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study	62
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	62
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection	62
Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up	61
Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial	61
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis	61
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells	60
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	60
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas	60
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data	60
COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals	59
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis	58
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)	57
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia	57
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant	55
In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice	55
American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation	54
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis	54
Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease	54
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy	54
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide	54
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles	53
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance	53
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients	53
Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19	53

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study	52
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma	52
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis	52
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP	52
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma	52
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma	52
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication	51
Lung megakaryocytes display distinct transcriptional and phenotypic properties	51
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML	50
Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells	50
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse	50
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis	50
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination	49
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies	48
Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium	48
CAR T-cell therapy for secondary CNS DLBCL	47
Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years	47
Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects	47
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition	46
Development of luspatercept to treat ineffective erythropoiesis	46
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation	46
Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients	46
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients	46
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma	45
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia	45
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes	45
First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings	45
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in	45
Optical genome mapping in acute myeloid leukemia: a multicenter evaluation	45
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients	45
Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice	45
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma	45
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia	45
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia	44
A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms	44
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies	44
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19	44
Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells	44
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant	44
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern	44
Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM	43
Treatment of allosensitized patients receiving allogeneic transplantation	43
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML	43
Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19	43
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study	43
Approach to the diagnosis of aplastic anemia	42
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma	42
Mesenchymal stromal cells in hematopoietic cell transplantation	42
Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era	42
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma	42
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma	42
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia	42
Inflammasome activation promotes venous thrombosis through pyroptosis	41
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing	41
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia	41
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report	41
Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia	41
Suboptimal iron deficiency screening in pregnancy and the impact of socioeconomic status in a high-resource setting	41
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified	41
A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy	41
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis	41
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study	41
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001	40
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity	40
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis	40
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax	40
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia	40
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases	40
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies	39
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma	39
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial	39
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition	39
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy	39
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification	39
Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes	39
Impaired exercise capacity in post–COVID-19 syndrome: the role of VWF-ADAMTS13 axis	39
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer	38
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19	38
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib	38
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial	37

Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19	37
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	37
Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets	37
A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2	36
Polarized mitochondria as guardians of NK cell fitness	36
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	36
Gut microbiome in pediatric acute leukemia: from predisposition to cure	36
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML	36
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL	36
High progression-free survival after intermediate intensity double unit cord blood transplantation in adults	36
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs	36
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance	35
Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial	35
The evolution of factor XI and the kallikrein-kinin system	35
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry	35
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy	34
Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study	34
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted	34
Effective anti-BCMA retreatment in multiple myeloma	34
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance	34
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma	34
A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells	34
CD200 expression marks leukemia stem cells in human AML	34
Abortive γδTCR rearrangements suggest ILC2s are derived from T-cell precursors	33
Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers	33
Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism	33
CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma	33
Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms	33
TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders	33
Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy	33
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors	33
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS	33
Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade	33
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study	33
Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy	32
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia	32
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis	32
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma	32
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study	32
Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ	32
COVID-19 vaccination in patients with immune thrombocytopenia	32
Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation	32
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol	31
Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse	31
The use of luspatercept for thalassemia in adults	31
Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations	31
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS	31
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase	31
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma	31
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days	31
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia	31
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation	31
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy	31
Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases	31
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements	31
Hematologic complications with age in Shwachman-Diamond syndrome	31
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses	30
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses	30
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study	30
Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis	30
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications	30
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia	30
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials	30
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome	30
Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients	30
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study	29
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia	29
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma	29
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML	29
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill pati	29
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis	29
Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review	29
ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome	29
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study	29
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease	29
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA	28
Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission	28
Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy	28
Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features	28
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia	28
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia	28
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes	28
Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma	28
Evans syndrome in adults: an observational multicenter study	28
The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker	28
Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma	28
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy	28
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma	28
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies	28
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen	27
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison	27
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active	27
CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy	27
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia	27
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development	27